Praluent's lower list price isn't yielding better sales yet

biopharmadive | April 26, 2019

Sanofi and Regeneron haven't had much luck unseating Amgen's lead position in the PCSK9 market. Total prescriptions for Praluent (alirocumab) were 7,098 for the week of April 19, or about half of the 14,409 seen with Repatha (evolocumab), according to Iqvia data collected by SVB Leerink. All three companies for some time resisted lowering list prices, citing clinical data that underscored how effective they were at curtailing the "bad," LDL form of cholesterol. Yet payers' reluctance to cover the medicines ultimately pushed the manufacturers to reconsider. Amgen in October cut the U.S. list price on Repatha to $5,850 from $14,523 in a bid to secure broader insurance coverage and, according to the company, lower out-of-pocket costs for patients on Medicare. Sanofi and Regeneron would follow suit several months later, citing the same reasons.

Spotlight

This video about the biotechnology in Rutgers University.

Spotlight

This video about the biotechnology in Rutgers University.

Related News

Pressure BioSciences Announces the Achievement of a Critical Milestone in Revolutionary Nanoemulsification Technology Development

Pressure BioSciences, Inc. | October 07, 2020

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ ("UST™")-based nanoemulsification system. Following achievement of this milestone, the Company has begun to build the initial "Alpha" unit of the commercial model. Once built, tested, and approved, the Company will immediately proceed to build an additional 15 ready-for-sale systems, thus enabling PBI to meet its goal of shipping the BaroShear K45 UST System in early (Q1/Q2) 2021. Based on the Company's patented UST platform, the BaroShear K45 is a unique breakthrough nanoemulsification system designed to resolve one of the most substantive problems facing manufacturers of biotherapeutic drugs, nutraceuticals (including hemp-derived CBD products), and other products containing oil-based active ingredients that are at best poorly soluble in water. As with any oil-based product, it is difficult for the water-based biochemistry of humans and other animals to access and absorb the active ingredients hidden within oil drops. Poor water solubility leads to lower absorption and bioavailability of active ingredients, which makes it particularly difficult to design and deliver proper dosing of the desired compound. More recently, growing science around nanoemulsion development has shown that oil-based active ingredients manufactured into high quality nanoemulsions have delivered dramatically increased absorption and bioavailability, resulting in higher quality finished products for the consumer.

Read More

MEDICAL

Precision NanoSystems is Now a Part of Danaher's Life Sciences Platform

Cytiva, Pall Corporation | June 02, 2021

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danaher Group Executive. "As mRNA has matured as a successful technology in some COVID vaccines, we see huge potential for this technology to accelerate other therapies. The work done thus far by the PNI team will also enable our customers at Cytiva and Pall to take a huge step forward in advancing their science to improve the lives of patients." James Taylor, co-founder, and CEO of Precision NanoSystems, says: "Over the last ten years, PNI has been a leading technology company, enabling the development of genetic medicines. Joining Danaher's Life Sciences platform allows our world-class team to accelerate and expand the work we do to support our customers with comprehensive technology platforms and the expertise to manufacture transformative medicines for the benefit of humanity. With the global reach of the Danaher Life Sciences platform and customers who are leaders in biotechnology, this is an incredible opportunity to bring PNI's innovations to market and expand our impact." The overall mRNA therapeutics and vaccines market was growing rapidly and accelerated with the development of COVID-19 mRNA vaccines. It is anticipated that mRNA technology will be used to develop other vaccines and to treat other conditions of high unmet medical need, such as cancer and genetic diseases. At present, most mRNA therapies and other types of genetic medicines in clinical development are designed to be delivered with the help of lipid nanoparticles (LNPs). PNI's Genetic Medicine Toolkit, including its proprietary GenVoyTM LNP delivery platform and NanoAssemblrTM microfluidic-based nanoparticle manufacturing platform, enables the rapid development of genetic medicines. PNI's validated technologies increase the stability, efficacy, yield, and quality of non-viral genetic medication and lower the barrier to develop these essential medicines. PNI is developing a new center of manufacturing excellence in Vancouver, which will proceed as planned. When complete, the biomanufacturing center will further advance Canadian therapeutic and vaccine manufacturing capabilities, broaden the domestic life sciences sector, create new jobs in the region, and foster a new generation of scientific talent. About Pall Pall Corporation may be a filtration, separation, and purification leader providing solutions to meet customers' critical fluid management needs across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety, and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. About Cytiva Cytiva is a global life science leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency, and capacity to research and manufacture workflows, enabling the development, manufacture, and delivery of transformative medicines to patients.

Read More

AI

Viva Biotech and BioMap Have Signed a Strategic Collaboration Agreement to Accelerate Early Drug Discovery Using AI Technology

Viva Biotech, BioMap | May 11, 2021

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing engine with Viva Biotech's structure-based drug discovery tool to jointly accelerate the R&D of novel drugs. Viva Biotech's President, Dr. Delin Ren, stated: "The combination of AI deep learning technologies and the SBDD technology platform is certain to have far-reaching consequences for drug design and R&D. The strategic partnership between Viva Biotech and BioMap is the ideal combination between these two technologies. It is anticipated that it will shorten the R&D period and increase the success rate of novel drug discovery." "High-quality biological data is the base of biocomputing platform development," said Liu Wei, co-founder, and CEO of BioMap. Viva Biotech has the most advanced protein structure analysis technologies and capabilities in the world. The partnership with Viva Biotech will allow BioMap to obtain high-quality macromolecular structure data in a high-throughput manner, especially for new targets, artificially designed antibody molecules, and target-drug complexes. The partnership, when combined with BioMap's strong computing power and algorithm development expertise, is expected to facilitate the development of BioMap's AI macromolecular drug platform, which will potentially lead to new drug development." AlxplorerBio and EPN, two biotech firms that Viva BioInnovator funded in and incubated, both attended the meeting and signed the collaboration agreement. About Viva Biotech Viva Biotech aims to become a place for innovative biotechnology companies from around the world. We have built a scalable business model that combines the conventional cash-for-service (CFS) model with the revolutionary equity-for-service (EFS) model. Under the CFS model, the Group offers global pharmaceutical clients a one-stop-shop for new drug discovery and production. The EFS business is committed to investing globally in biotech research that provides novel solutions to unmet medical needs in a variety of therapeutic areas. Viva Biotech has offered drug development and manufacturing services to 1,252 pharmaceutical clients worldwide as of December 31, 2020, worked on over 1,500 independent drug targets, delivered over 21,000 independent protein structures, and incubated/invested in 67 biotech firms. About BioMap BioMap is China's first biocomputing-driven biotech firm, led as chairman by Baidu CEO Robin Li and co-founder and CEO by Baidu Ventures' former CEO Liu Wei. BioMap was established during a period of growth in biological data. Our goal is to use AI and data to significantly improve the lives of patients. BioMap, positioned as a data-driven company, is speeding the R&D phase of early screening/diagnosis, drug discovery, and other precision medicine products by leveraging high-performance biocomputing and AI capabilities, gaining insights from our unique and vast library of population and molecular data sets. We are concentrating our efforts on developing our internal AI engine and data collection capabilities to curate our proprietary insights for difficult diseases.

Read More